Trump Cannabis Rescheduling Plan Draws Mixed Industry Response

The cannabis industry finds itself cautiously optimistic about former President Trump's stated support for marijuana rescheduling, though sector experts argue the approach represents only partial reform. Trump's position on moving cannabis from Schedule I to a lower classification under the Controlled Substances Act marks a notable shift from his previous administration's stance, yet falls considerably short of the comprehensive federal legalization many industry stakeholders demand.

Rescheduling would address some immediate pain points for cannabis operators, particularly the punitive 280E tax provision that prevents businesses from deducting standard operating expenses. This change could dramatically improve profit margins for multi-state operators like Curaleaf Holdings (CURLF), Green Thumb Industries (GTBIF), and Trulieve Cannabis (TCNNF), which currently face effective tax rates exceeding 70% in many cases. However, rescheduling to Schedule III would maintain federal prohibition while creating a complex regulatory framework that could limit interstate commerce and banking access.

The industry's lukewarm reception reflects broader frustration with incremental policy changes that fail to unlock cannabis's full economic potential. Banking restrictions would likely persist under rescheduling, forcing operators to continue managing primarily cash-based businesses with limited access to traditional financial services. Interstate commerce restrictions would remain intact, preventing the economies of scale that could drive down consumer prices and improve operational efficiency across state lines.

Cannabis equity markets have shown sensitivity to federal policy signals, with the AdvisorShares Pure US Cannabis ETF (MSOS) experiencing volatility around regulatory announcements. While rescheduling represents movement toward normalization, institutional investors remain hesitant to fully embrace the sector without complete federal legalization. The continued Schedule III classification would maintain enough regulatory uncertainty to keep many institutional capital sources on the sidelines.

The industry's measured response underscores a strategic calculation that partial reform may actually delay comprehensive legalization by reducing political pressure for complete federal cannabis policy overhaul. Operators and investors increasingly view federal legalization as the catalyst needed to unlock true market potential, including interstate commerce, institutional investment, and elimination of the tax disadvantages that currently constrain profitability across the sector.